 Corcept Therapeutics Incorporated NASDAQ: CORT has announced that data from the Phase 2 trial of relacorilant plus nab-paclitaxel were presented at the European Society for Medical Oncology ESMO21 Congress 2021. The trial included 178 patients with recurrent platinum-resistant ovarian cancer. 